Nigeria's tax framework has introduced a new incentive for companies that invest in research and development activities. Under the provision, eligible businesses may claim a deduction of up to 5 per cent of their annual turnover on qualifying R&D expenditures.
The deduction is designed to encourage innovation, strengthen domestic industrial capacity, and align Nigeria's tax regime with global best practices that reward investments in knowledge and technology. For businesses operating in manufacturing, technology, pharmaceuticals, and other innovation-driven sectors, the incentive represents a meaningful opportunity to reduce taxable income while advancing product development and process improvement.
To benefit from the deduction, companies must ensure that their R&D activities meet the statutory definition of qualifying expenditure. This typically includes costs incurred directly in the pursuit of scientific or technological advancement, such as salaries of research personnel, materials consumed in the research process, and overheads reasonably attributable to R&D functions. Routine market research, quality control testing, and cosmetic modifications to existing products generally fall outside the scope of qualifying expenditure.
Taxpayers are advised to maintain robust documentation to substantiate claims. This includes detailed project records, timesheets for staff engaged in R&D, invoices for materials and equipment, and evidence linking expenditure to specific research objectives. The Federal Inland Revenue Service is expected to scrutinise R&D claims closely, and inadequate record-keeping may result in disallowance upon audit.
The 5 per cent turnover cap ensures that the deduction remains proportionate to the scale of a company's operations. Businesses with significant turnover but modest R&D spending will find the cap non-restrictive, while those with concentrated R&D programmes should model the interaction between the turnover cap and their overall tax position.
Interaction with other incentives, such as pioneer status and investment allowances, warrants careful planning. Companies enjoying multiple tax reliefs should confirm whether the R&D deduction can be claimed concurrently or whether stacking restrictions apply.
As the provision takes effect, professional guidance is essential to navigate compliance requirements and maximise available relief.
